

Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

AETERNA LABORATORIES INC
Form 6-K
May 30, 2003

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of May 2003

AETERNA LABORATORIES INC.

(Translation of registrant's name into English)

1405, BOUL. DU PARC-TECHNOLOGIQUE
QUEBEC, QUEBEC
CANADA, G1P 4P5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.

Form 20-F / / Form 40-F /X/

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes / / No /X/

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-_____

DOCUMENTS INDEX

DOCUMENTS DESCRIPTION

Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

-
1. Press Release dated May 29, 2003: AETerna Laboratories holds Annual Meeting
-

[LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA LABORATORIES HOLDS ANNUAL MEETING

The Company presents its new position in the international biopharmaceutical sector

Nobel Prize winner joins its Scientific Advisory Board

MONTREAL, QUEBEC, MAY 29, 2003 - At the annual meeting today, Gilles Gagnon, President and Chief Executive Officer of AETerna Laboratories Inc. (TSX: AEL, NASDAQ: AELA) reminded shareholders of the principal growth and added-value creation objectives of the Company. "The integration of our subsidiary Zentaris, together with our strategic growth plan that is tightly bound to acquisitions, has established AETerna on the international stage. The competence and expertise we have developed over the years allow us to position AETerna as a biopharmaceutical company specialized in the development of innovative treatments in oncology and endocrinology, from drug discovery to market approval."

The Company enjoys a solid financial situation with cash assets in excess of \$50 million. "In addition to this liquidity, our biopharmaceutical segment and our subsidiary Atrium generate substantial revenues that ensure our financial stability," continued Mr. Gagnon. Atrium performed exceptionally well in 2002 with revenues in excess of \$100 million. Furthermore, we have a 12-product pipeline whose development and marketing are supported by an international network of 14 partners, mostly pharmaceutical companies."

OTHER SIGNIFICANT EVENTS OF THE ASSEMBLY

STRATEGIC PARTNERSHIPS

During the last year, two other agreements were signed with the pharmaceutical companies Mayne Group (Australia) and LG Life Sciences (Korea) for the eventual marketing of Neovastat. "Our partnership agreements allow us to cover 50% of the world market and to reach the plateau of \$50 million in milestone payments. We are pursuing our discussions with other eventual partners in order to complete our network for Neovastat," explained Mr. Gagnon. Our Phase III trial in lung cancer, sponsored by the U.S. National Cancer Institute (NCI) and the Phase III clinical study in kidney cancer are ongoing. In fact, our Phase III trial in kidney cancer will be completed in the next few months and positive results may enable us to inaugurate this new therapeutic class.

Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

In endocrinology, Cetrotide(R), a product used for IN VITRO fertilization, should make its entry on the Japanese market in the near future, as a result of partnerships with pharmaceuticals Shionogi and Nippon Kayaku. The Swiss company Seroxo is currently marketing Cetrotide(R) worldwide, except for Japan.

NOBEL PRIZE LAUREATE

Dr. Jurgen Engel, Zentaris' Managing Director and AETerna's Executive Vice President, Global R&D and Chief Operating Officer, announced the appointment of Dr. Harmut Michel to the Company's Scientific Advisory Board. Dr. Michel, Director of the prestigious Max-Planck Institute for Biophysics in Frankfurt, Germany, was awarded the Nobel Prize in chemistry in 1988 for his scientific research in protein crystallization. "We are very proud to welcome this distinguished researcher to our Scientific Advisory Board," stated Dr. Engel. "Dr. Michel has unique knowledge in molecular structure which could improve the comprehension of some of our products and enhance their development."

CONVERSION OF MULTIPLE VOTING SHARES

Dr. Eric Dupont, AETerna's Chairman of the Board, announced the conversion of all of his 4,725,000 multiple voting shares (10 votes per share) into the same number of subordinate voting shares (1 vote per share). This conversion does not involve any sale of shares by Dr. Dupont who still owns the same number of shares in AETerna while maintaining his stake in the Company at 11.6%. This conversion will leave AETerna with only one class of outstanding voting shares, i.e. common shares with one vote per share. "AETerna has now attained depth and maturity, thanks to a highly-experienced management team that has been built from within the biopharmaceutical industry," said Dr. Dupont. "Although I remain quite active in questions concerning the general orientation of the Company, I feel that the time has come to pass the torch to the second generation of managers. I am convinced that this decision will serve the best interests of the Company's shareholders," concluded Dr. Dupont.

This conversion releases Dr. Dupont from his obligation under previously signed contractual agreements to obtain the prior consent of SGF Sante and the Solidarity Fund QFL before exercising his voting rights on important matters concerning AETerna, but it does not affect the rights of these two principal shareholders to conserve their representation on AETerna's Board of Directors, provided that SGF Sante maintains a participation of at least 5% and that the Solidarity Fund QFL holds at least 499,999 shares of AETerna's subordinate voting stock.

This is an important step that is to be viewed in the larger context of the many steps taken by the Company, over the years, to adopt an irreproachable line of conduct concerning Corporate Governance. We emphasize here that the Board of Directors has always been composed of a majority of outside directors, unrelated to the Company; the position of Chairman of the Board and President and Chief Executive Officer of the Company has been divided in two; and the Audit Committee has been formed, consisting of external directors and not related to the Company, in addition to a Corporate Governance Committee with a majority of external directors and not related to the Company.

ABOUT AETERNA LABORATORIES INC.

AETerna is a biopharmaceutical company focused on the development of novel

Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

therapeutic treatments, mainly in oncology and endocrinology. The product pipeline includes 12 products ranging from preclinical stage up to marketing. AEterna has strategic worldwide partners such as Access Oncology, Ardana Bioscience, Baxter Healthcare S.A., German Remedies Ltd., Grupo Ferrer Internacional S.A., Hainan Chang An Pharmaceutical Ltd., LG Life Sciences Ltd., Mayne Group, Medac GmbH, Nippon Kayaku, Serono International S.A., Shionogi & Co. Ltd, Solvay Pharmaceuticals B.V. and Teikoku Hormone Mfg. Co. Ltd.

AEterna owns 100% of the biopharmaceutical company Zentaris GmbH, based in Frankfurt, Germany.

AEterna also owns 61.8% of Atrium Biotechnologies Inc., which develops and markets nutritional supplements, as well as active ingredients and fine chemicals intended for the cosmetics, nutrition, fine chemicals and pharmaceuticals industries. Atrium markets over 500 products in 20 countries to industry leaders such as Estee Lauder, L'Oreal, Clarins, Chanel, Aventis, SanofiSynthelabo and Nestle.

AEterna and its entities have 270 employees in Canada and Europe.

AEterna shares are listed on the Toronto Stock Exchange (AEL) and the NASDAQ National Market (AELA).

News releases and additional information about AEterna are available on its Web site at: www.aeterna.com.

NOTE: GILLES GAGNON, AETERNA'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL MAKE A PRESENTATION TO THE INVESTMENT COMMUNITY OF THE UNITED STATES IN NEW YORK CITY, ON JUNE 4, 2003, AT 2 P.M. AT THE GRAND HYATT HOTEL, DURING THE UBS WARBURG GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of the business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's ongoing quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

- 30 -

CANADA

MEDIA RELATIONS:

INVESTOR RELATIONS:

Edgar Filing: AETERNA LABORATORIES INC - Form 6-K

Paul Burroughs
Tel.: (418) 652-8525 ext. 406
Cell.: (418) 573-8982
Fax: (418) 577-7700
E-mail: paul.burroughs@aeterna.com

Jacques Raymond
Tel.: (418) 652-8525 ext 360
Cell.: (514) 703-5654
Fax: (418) 577-7700
E-mail: jacques.raymond@aeterna.com

USA
THE INVESTOR RELATIONS GROUP
Lisa Lindberg
Tel.: (212) 825-3210
Fax: (212) 825-3229
E-mail: TheProTeam@aol.com

EUROPE
INVESTOR RELATIONS
Matthias Seeber
Tel.: 011 49 69 4 26 02 34 25
Fax: 011 49 69 4 26 02 34 44
E-mail: matthias.seeber@zentaris.de

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA LABORATORIES INC.

Date: May 29, 2003

By: /s/ CLAUDE VADBONCOEUR

Claude Vadboncoeur
Vice President, Legal Affairs and
Corporate Secretary